JMP reiterates Human Genome at market outperform

Human Genome Sciences Inc. was reiterated at market outperform with a $15 target price by JMP Securities analysts Charles C. Duncan and Anthony Ostrea after the company announced positive results from key clinical programs in rheumatoid arthritis and oncology. Based on these positive signals and the stock's recent climb (up 13% since Oct. 13) from a yearly low, JMP said it expects enhanced investor confidence in the company's product pipeline may continue to drive share appreciation. Shares of the Rockville, Md.-based biopharmaceutical company were up 54 cents, or 5.98%, at $9.57 on volume of 4,587,912 shares versus the three-month running average of 3,574,190 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.